Business Monitor International


Morocco Pharmaceuticals & Healthcare Report

Published 15 October 2014

  • 113 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Morocco Pharmaceuticals & Healthcare Report

BMI View:   As Morocco ' s economic conditions improve towards the end of 2014 and the rate of decline in pharmaceutical sales slows, we hold an overall positive outlook for the market over the medium - to - long term, which will be driven by the growing middle class. However, the country ' s inefficient regulatory environment ,   coupled   with a weak healthcare infrastructure and poor health insurance cover , will continue to create difficult operating conditions for drugmakers, impeding the market ' s potential.

Headline Expenditure Projections

  • Pharmaceuticals: MAD9.32bn (USD1.11bn) in 2013 to MAD9.36bn (USD1.12bn) in 2014; +0.4% in local currency terms and +0.8% in US dollar terms.

  • Healthcare: MAD57.78bn (USD6.88bn) in 2013 to MAD62.66bn (USD7.49bn) in 2014; +8.4% in local currency terms and +8.8% in US dollar terms. Forecast higher than in Q214 due to upward revision of historical figures for pharmaceutical market.

Risk/Reward Rating

In our latest proprietary Pharmaceutical Risk/Reward Ratings (RRR), Morocco continues to be viewed as a moderately attractive pharmaceutical market in the Middle East and Africa (MEA) region, from a longer-term perspective. Morocco ranks 15 th in the region, out of the 31 countries assessed in our ratings matrix, with a score of 42.3 out of 100. The market's constraints include low per capita consumption and an underdeveloped reimbursement system, although such factors are to a degree offset by a relatively predictable operating environment.

Key Trends And Developments

In September 2014, Abderrahmane Maâroufi, director of the Epidemiology and Fight against Diseases at the health ministry, stated that Morocco had launched a preparedness and response plan for Ebola Virus Disease (EVD), reports Morocco Gazette. The plan is based on preventing the introduction of EVD and risk detection and analysis. The health ministry has implemented control measures that target air traffic and ports that receive cargo from West Africa....

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Morocco 2010-2018)
17
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Morocco 2010-2018)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
21
Patented Drug Market Forecast
21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
22
Generic Drug Market Forecast
23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
25
OTC Medicine Market Forecast
25
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Morocco 2010-2018)
26
Pharmaceutical Trade Forecast
27
Table: Pharmaceutical Trade Data And Forecasts (Morocco 2012-2018)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Morocco 2012-2018)
29
Other Healthcare Data
30
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
32
Economic Analysis
32
Table: VARIOUS COUNTRIES - REAL GDP GROWTH, %
33
Industry Risk Reward Ratings
42
Middle East & Africa Risk/Reward Index
42
Morocco Risk/ Reward Ratings
49
Rewards
49
Risks
50
Market Overview
52
Industry Trends And Developments
53
Epidemiology
53
Healthcare Sector
56
Healthcare Insurance
59
Recent Health Insurance Developments
62
Research & Development
65
Clinical Trials
66
Regulatory Development
67
Intellectual Property Regime
68
Pricing Regime
68
Reimbursement Regime
70
Competitive Landscape
73
Pharmaceutical Industry
73
Table: Morocco's Select Pharmaceutical Industry Indicators
73
Table: Members Of MIS, 2011
74
Table: Members Of AMIP, 2011
75
Domestic Pharmaceutical sector
75
Foreign Pharmaceutical Companies
76
Pharmaceutical Wholesale
78
Pharmaceutical Retail
79
Company Profile
81
Sothema
81
Laprophan
84
Promopharm
87
Sanofi
89
Pfizer
93
GlaxoSmithKline
96
Ranbaxy
98
Demographic Forecast
100
Table: Morocco's Population By Age Group, 1990-2020 ('000)
101
Table: Morocco's Population By Age Group, 1990-2020 (% of total)
102
Table: Morocco's Key Population Ratios, 1990-2020
103
Table: Morocco's Rural And Urban Population, 1990-2020
103
Glossary
104
Methodology
106
Pharmaceutical Expenditure Forecast Model
106
Healthcare Expenditure Forecast Model
106
Notes On Methodology
107
Risk/Reward Ratings Methodology
108
Ratings Overview
109
Table: Pharmaceutical Risk/Reward Ratings Indicators
109
Indicator Weightings
110

The Morocco Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Morocco Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Moroccan pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Morocco to test other views - a key input for successful budgeting and strategic business planning in the Moroccan pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Moroccan pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Morocco.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc